Michael O'Dwyer to Bortezomib
This is a "connection" page, showing publications Michael O'Dwyer has written about Bortezomib.
Connection Strength
0.395
-
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):847-852.
Score: 0.198
-
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Adv. 2019 06 25; 3(12):1815-1825.
Score: 0.160
-
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. BMC Med Res Methodol. 2018 06 28; 18(1):66.
Score: 0.037